Damora Therapeutics (DMRA) vs Kardigan (KARD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Kardigan is the larger company by market cap ($1.29 billion vs $1.25 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DMRA | KARD |
|---|---|---|
| Share price | $20.24 | $13.83 |
| Market cap | $1.25B | $1.29B |
| 1-day change | +3.53% | +2.52% |
| 5-year return | -76.33% | — |
| EPS (TTM) | $-0.25 | $-10.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $38.33 | $27.00 |
| 52-week low | $4.95 | $12.32 |
| Distance from 52-week high | -47.19% | -48.78% |
| Average volume | 542.78K | 477.59K |
| Shares outstanding | 61.74M | 93.50M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
DMRA vs KARD FAQ
Which is bigger, Damora Therapeutics or Kardigan?
Kardigan (KARD) is larger, with a market capitalization of $1.29B compared with $1.25B for Damora Therapeutics (DMRA).
Are Damora Therapeutics and Kardigan in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.